Frontlight ResearchEarly access
TerminatedPhase 1
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Key facts
- Who runs it
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 192 people enrolled
- Started
- 9 Jun 2021
- Ended
- 30 Dec 2025
- Type of study
- Interventional
- Treatments tested
- TQB3720
- Record updated
- 31 March 2026
- Why it stopped
- Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
Who can take part
- Age
- 18 years to 80 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- 1. Histologically or cytologically confirmed prostate carcinoma. 2.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy ≥12 weeks; 3.Testosterone levels < 50 ng/dL. 4. Has received ≥1 previous regimens for metastatic castration-resistant prostate cancer; 5.Male subjects should agree to use an adequate method of contraception starting with signing ICF through 6 months after the last dose of study; 6.Understood and signed an informed consent form
Who cannot take part
- -1.Has symptomatic brain metastases or control of symptoms < 1 month. 2.Has other malignancies within 3 years. 3.Has used second-generation androgen receptor antagonists. 4. Abnormal liver function. 5. Abnormal renal function. 6. Has received any other investigational drug within 30 days weeks before first dose
- According to the judgement of the researchers, there are other factors that subjects are not suitable for the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.
The group in the trial
- TQB3720 tabletsTreatment being tested
TQB3720 tablets administered orally, once daily in 28-day cycle.
Treatment: TQB3720
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
- Record updated
- 31 March 2026